Answers are grounded in this paper and cite their sources.
Herein, we report a non-fluorescent 2,1,3-benzothiadiazole (BTD) derivative, BTD-PhCOOH, as a protein-triggered fluorogenic platform for SARS-CoV-2 spike protein detection. Direct coupling under mild refrigerated conditions afforded the BTD-Spike conjugate, producing an intense green fluorescence signal and demonstrating efficient fluorescence turn-on after protein ligation. Solvent-accessible surface area analysis (SASA) identified Lys529 as the most accessible lysine residue, providing a structural rationale for conjugate formation. In MCF-7 cells, BTD-Spike enabled time-dependent visualization of spike-associated cellular interactions, with membrane-associated fluorescence after 30 min and a more defined peripheral and intracellular punctate pattern after 60 min. In mice, systemic intravenous administration established the current sensitivity limits of visible-range whole-body and ex vivo organ fluorescence imaging, as treated animals could not be clearly distinguished from controls under these acquisition conditions. Importantly, higher-resolution confocal analysis of fixed brain tissue revealed localized fluorescence differences between treated and control samples. Additionally, direct intracerebroventricular administration enabled brain-level detection of both BTD-Spike and BTD-labeled amyloid-β, generating qualitatively distinct fluorescence patterns in the central nervous system. Overall, BTD-PhCOOH establishes a protein-activated fluorescence platform strongly supported by chemical, photophysical, computational, and cellular validation, while the brain-detection experiments highlight its potential for probing protein-associated signals in complex biological environments.
No takes yet. Share an insight, caveat, or question.
Neto et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: